MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 207 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $215,530 | +180.2% | 1,476 | +343.2% | 0.00% | – |
| Q2 2023 | $76,923 | +24.0% | 333 | +30.1% | 0.00% | – |
| Q1 2023 | $62,010 | -58.3% | 256 | -50.0% | 0.00% | – |
| Q4 2022 | $148,581 | +132.2% | 512 | -47.6% | 0.00% | – |
| Q3 2022 | $64,000 | -9.9% | 977 | -1.1% | 0.00% | – |
| Q2 2022 | $71,000 | -30.4% | 988 | -4.8% | 0.00% | – |
| Q1 2022 | $102,000 | +30.8% | 1,038 | +11.0% | 0.00% | – |
| Q4 2021 | $78,000 | +11.4% | 935 | +8.0% | 0.00% | – |
| Q3 2021 | $70,000 | +133.3% | 866 | +183.0% | 0.00% | – |
| Q2 2021 | $30,000 | 0.0% | 306 | +17.2% | 0.00% | – |
| Q1 2021 | $30,000 | -16.7% | 261 | -19.4% | 0.00% | – |
| Q4 2020 | $36,000 | +125.0% | 324 | +134.8% | 0.00% | – |
| Q3 2020 | $16,000 | +45.5% | 138 | +38.0% | 0.00% | – |
| Q2 2020 | $11,000 | -68.6% | 100 | -80.9% | 0.00% | – |
| Q1 2020 | $35,000 | – | 523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |